Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BYSI, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Plinabulin | Non-Small Cell Lung Cancer | Phase 3 · NCT02504489 | Completed |
| Doxorubicin | Chemotherapy-induced Neutropenia | Phase 3 · NCT03294577 | Unknown |
Also used in these trials (approved or third-party drugs, not BYSI's own candidates): Docetaxel Anhydrous, Pegfilgrastim, Ipilimumab, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BYSI holds $6.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 80 · High
These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BYSI files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BYSI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →